Drug interactions between Diamox and Topamax
| Results for the following 2 drugs: |
|---|
| Diamox (acetazolamide) |
| Topamax (topiramate) |
Interactions between your selected drugs
acetazolamide ↔ topiramate
Applies to:Diamox (acetazolamide) and Topamax (topiramate)
GENERALLY AVOID: Concomitant use of topiramate or zonisamide with carbonic anhydrase inhibitors may increase the risk of kidney stone formation. Topiramate and zonisamide are themselves weak carbonic anhydrase inhibitors, and agents in this class can promote stone formation by reducing urinary citrate excretion and increasing urinary pH. Coadministration with other carbonic anhydrase inhibitors may also potentiate the risk of oligohidrosis and hyperthermia associated occasionally with the use of topiramate and zonisamide, particularly in pediatric patients. Carbonic anhydrase inhibitors can alter electrolyte and fluid balance and predispose patients to heat-related disorders, especially in hot weather. Oligohidrosis and hyperthermia are sometimes associated with serious sequelae but may be preventable by prompt recognition of symptoms and appropriate treatment.
MANAGEMENT: Use of topiramate or zonisamide with other carbonic anhydrase inhibitors should be avoided or otherwise approached with caution. Increased fluid intake is recommended to increase urinary output, which lowers the concentration of substances involved in stone formation. Patients, particularly pediatric patients, should be monitored closely for evidence of decreased sweating and increased body temperature, especially in warm or hot weather. Proper hydration before and during vigorous activities or exposure to warm temperatures is recommended. Patients (or their guardians or cavegivers) should contact their physician immediately if they develop signs or symptoms of kidney stones such as sudden back pain, abdominal pain and/or blood in the urine, of if they are not sweating as usual, with or without a fever.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
